tiprankstipranks
Advertisement
Advertisement
Biogen reports Q1 adjusted EPS $3.57, consensus $2.95
PremiumThe FlyBiogen reports Q1 adjusted EPS $3.57, consensus $2.95
4M ago
Wells Fargo downgrades Apellis to Equal Weight following Biogen’s acquisition
Premium
The Fly
Wells Fargo downgrades Apellis to Equal Weight following Biogen’s acquisition
4M ago
Apellis downgraded to Equal Weight from Overweight at Wells Fargo
Premium
The Fly
Apellis downgraded to Equal Weight from Overweight at Wells Fargo
4M ago
Apellis downgraded to Neutral from Buy at Roth Capital
PremiumThe FlyApellis downgraded to Neutral from Buy at Roth Capital
5M ago
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
Premium
The Fly
Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
5M ago
Biogen price target raised to $275 from $250 at Oppenheimer
Premium
The Fly
Biogen price target raised to $275 from $250 at Oppenheimer
5M ago
Hold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts
PremiumRatingsHold Rating on Apellis Reflects Biogen Takeover Cap on Upside and Limited Near-Term Catalysts
5M ago
Apellis Pharmaceuticals to be Acquired by Biogen in Merger
Premium
Company Announcements
Apellis Pharmaceuticals to be Acquired by Biogen in Merger
5M ago
Apellis downgraded to Neutral from Overweight at Cantor Fitzgerald
Premium
The Fly
Apellis downgraded to Neutral from Overweight at Cantor Fitzgerald
5M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100